Monday, October 14, 2024
spot_imgspot_imgspot_imgspot_img
HomeNewsFDA approves oral diabetes drug from Novo Nordisk

FDA approves oral diabetes drug from Novo Nordisk

Scroll back up to restore default view.

(Reuters) – The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk’s diabetes drug semaglutide, a boost for the Danish drugmaker which hopes to transform the market by offering patients a non-injectable treatment.

The world’s biggest producer of diabetes drugs already sells an injectable once-weekly version of semaglutide under the brand name Ozempic at nearly $800 per month.

The new oral treatment, called Rybelsus, stimulates insulin production in patients with type 2 diabetes and is meant to be taken once a day. (http://bit.ly/2kWSKJH)

(Reporting by Tamara Mathias in Bengaluru; Editing by Shailesh Kuber)

Source – Reuters

Reuters

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -
Google search engine

Most Popular

Recent Comments

sildenafil generic australia on Abandoned IDP Camp Discovered In Kaduna
Daniel Grace on WORLD DOWN SYNDROME DAY
Danjuma Saddiq on THE CONSPIRACY IN SOKOTO
Yakkon Damaryam on The War against Glaucoma
Shehu Danbaki on IMG-20181125-WA0070
Seth Yamusa on Hon Danjuma Peter Averik
Ibraheem Awowole on MEET OUR PATHFINDER FOR OSUN 2018
Amb. Hoom'Suk. on Sarauniya Beauty Pageant 2017